Cannabinoids for clinicians: The rise and fall of the cannabinoid antagonists

European Journal of Endocrinology

Volumn 161, Issue 5, 2009, Pages 655-662

  Butler, Helen ^a   Korbonits, Márta ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 3 HEXYL 1H 1,2,4 TRIAZOLE; ALPHA INTERMEDIN; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CARBOHYDRATE; E 6837; ENDOCANNABINOID; FATTY ACID AMIDASE; GHRELIN; GLUCOCORTICOID; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; LIPID; NEUROPEPTIDE Y; NEUROTRANSMITTER; OREXIN; PLACEBO; POTASSIUM CHANNEL; RIMONABANT; SEROTONIN AGONIST; TARANABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; ANTIOBESITY AGENT; CANNABINOID; CANNABINOID RECEPTOR;

ANXIETY DISORDER; APPETITE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIET THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; ENZYME ACTIVATION; EXERCISE; FOOD INTAKE; HUMAN; HYPERLIPIDEMIA; LIPID OXIDATION; MENTAL DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLEEP DISORDER; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; WEIGHT REDUCTION; DRUG ANTAGONISM; DRUG EFFECT; EATING; METABOLISM; PHYSIOLOGY;

ANTI-OBESITY AGENTS; CANNABINOIDS; EATING; ENDOCANNABINOIDS; HUMANS; OBESITY; RECEPTORS, CANNABINOID;

EID: 70449699754     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0511     Document Type: Review

References (84)

1. Piomelli D. The endocannabinoid system: a drug discovery perspective. Current Opinion in Investigational Drugs 2005 6 672-679. (Pubitemid 40904037)
2. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK & Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation 2003 112 423-431. (Pubitemid 38063771)
3. Duffy D & Rader D. Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. Trends in Cardiovascular Medicine 2007 17 35-43. (Pubitemid 46210169)
4. Perkins JM & Davis SN. Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Current Diabetes Reports 2008 8 12-19.
5. Paton WD. Cannabis and its problems. Proceedings of the Royal Society of Medicine 1973 66 718-721.
6. Zias J, Stark H, Sellgman J, Levy R, Werker E, Breuer A & MechoulamR. Early medical use of cannabis. Nature 1993 363 215.
7. Gaoni Y & Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. Journal of the American Chemical Society 1971 93 217-224.
8. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC & Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990 346 561-564. (Pubitemid 20238806)
9. Munro S, Thomas KL & Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993 365 61-65. (Pubitemid 23305569)
10. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R & Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 2002 54 161-202.
11. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. International Journal of Obesity 2006 30 S13-S18.
12. 1)- immunoreactive axons in the mouse hypothalamus. Journal of Comparative Neurology 2007 503 270-279.
13. 2 receptors. Science 2005 310 329-332.
14. Pacher P, Batkai S & Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 2006 58 389-462. (Pubitemid 44394908)
15. Pagotto U, Marsicano G, Cota D, Lutz B & Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews 2006 27 73-100. (Pubitemid 43228239)
16. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE & Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004 47 345-358. (Pubitemid 39298276)
17. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D & Hogestatt ED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999 400 452-457.
18. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T & Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology 2007 152 1092-1101. (Pubitemid 350166046)
19. Pacher P, Batkai S & Kunos G. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 2005 48 1130-1138. (Pubitemid 40725985)
20. O'Sullivan SE, Kendall DA & Randall MD. Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). British Journal of Pharmacology 2004 141 803-812.
21. 1) receptors. Psychopharmacology 1999 143 315-317.
22. Jamshidi N & Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology 2001 134 1151-1154. (Pubitemid 33097243)
23. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB & Korbonits M. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. Journal of Biological Chemistry 2005 280 25196-25201. (Pubitemid 40934612)
24. Kola B. Role of AMP-activated protein kinase in the control of appetite. Journal of Neuroendocrinology 2008 20 942-951. (Pubitemid 351859112)
25. 1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. Journal of Biological Chemistry 2006 281 38812-38824.
26. 2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Molecular Pharmacology 2005 67 1697-1704.
27. 1 receptor: electrophysiological and FRET assay analysis. Journal of Pharmacological Sciences 2008 108 308-319.
28. Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, Amin F, Harvey-White J, Liposits Z, Kunos G, Grossman AB, Fekete C & Korbonits M. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 2008 3 e1797. (Pubitemid 351917350)
29. Hermann H, Marsicano G & Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002 109 451-460. (Pubitemid 34121997)
30. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, Iwabu M, Awazawa M, Katsuyama H, Hasegawa C, Tokuyama K, Moroi M, Sugi K, Yamauchi T, Noda T, Nagai R, Terauchi Y, Tobe K, Ueki K & Kadowaki T. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. Journal of Biological Chemistry 2009 284 1803-1812.
31. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M & Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005 30 1216-1221. (Pubitemid 40720981)
32. Maccarrone M, Fride E, Bisogno T, Bari M, Cascio MG, Battista N, Finazzi Agro A, Suris R, Mechoulam R & Di Marzo V. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Molecular Human Reproduction 2005 11 21-28. (Pubitemid 40330999)
33. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T & Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001 410 822-825. (Pubitemid 32303781)
34. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F & Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology 2003 63 908-914. (Pubitemid 36368998)
35. Gamber KM, Macarthur H & Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005 49 646-652. (Pubitemid 41208286)
36. 1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 2004 145 3224-3231.
37. 1 antagonist, SR141716. Journal of Biological Chemistry 2003 278 23731-23737.
38. Di S, Malcher-Lopes R, Halmos KC & Tasker JG. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. Journal of Neuroscience 2003 23 4850-4857.
39. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG & Tasker JG. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005 146 4292-4301.
40. 1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience 1999 11 4213-4225.
41. Melis T, Succu S, Sanna F, Boi A, Argiolas A & Melis MR. The cannabinoid antagonist SR 141716A (rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neuroscience Letters 2007 419 231-235. (Pubitemid 46755483)
42. Gerard CM, Mollereau C, Vassart G & Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal 1991 279 129-134.
43. 1 receptors in human ileum. British Journal of Pharmacology 1998 125 1393-1395.
44. 1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. Journal of Clinical Investigation 2008 118 3160-3169.
45. 1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. International Journal of Obesity 2005 29 183-187.
46. 2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006 39 155-162.
47. Despres JP. The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Critical Pathways in Cardiology 2007 6 46-50. (Pubitemid 46878231)
48. 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation 2005 115 1298-1305.
49. 1 receptor antagonist, in diet-induced obese mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2003 284 R345-R353.
50. Greenberg I, Kuehnle J, Mendelson JH & Bernstein JG. Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology 1976 49 79-84.
51. 1 cannabinoid receptor-dependent modulation of feeding. Journal of Neuroscience 2002 22 9612-9617.
52. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G & Vettor R. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. Journal of Clinical Endocrinology and Metabolism 2007 92 4810-4819. (Pubitemid 350223464)
53. 1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal 2005 19 1567-1569.
54. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P & Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. Journal of Clinical Endocrinology and Metabolism 2006 91 3171-3180. (Pubitemid 44271774)
55. Jesudason D & Wittert G. Endocannabinoid system in food intake and metabolic regulation. Current Opinion in Lipidology 2008 19 344-348.
56. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet- Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrie P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM & Bensaid M. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007 46 122-129. (Pubitemid 47171928)
57. Banasch M, Goetze O, Schmidt WE & Meier JJ. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver International 2007 27 1152-1155. (Pubitemid 47399452)
58. Di Marzo V & Matias I. Endocannabinoid control of food intake and energy balance. Nature Neuroscience 2005 8 585-589. (Pubitemid 40594198)
59. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM & Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005 54 2838-2843. (Pubitemid 41401077)
60. Sipe JC, Waalen J, Gerber A & Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). International Journal of Obesity 2005 29 755-759. (Pubitemid 40897010)
61. Jensen DP, Andreasen CH, Andersen MK, Hansen L, Eiberg H, Borch-Johnsen K, Jorgensen T, Hansen T & Pedersen O. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. Journal of Molecular Medicine 2007 85 445-449. (Pubitemid 46701653)
62. Russo P, Strazzullo P, Cappuccio FP, Tregouet DA, Lauria F, Loguercio M, Barba G, Versiero M & Siani A. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. Journal of Clinical Endocrinology and Metabolism 2007 92 2382-2386. (Pubitemid 46997151)
63. 1) receptors. Psychopharmacology 1997 132 104-106.
64. Simiand J, Keane M, Keane PE & Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behavioural Pharmacology 1998 9 179-181. (Pubitemid 28186515)
65. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Neliat G, Arnone M, Finance O, Soubrie P & Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 1994 350 240-244. (Pubitemid 24268029)
66. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J & Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Journal of the American Medical Association 2006 295 761-775. (Pubitemid 43244304)
67. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O & Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 365 1389-1397. (Pubitemid 40523733)
68. Scheen AJ, Finer N, Hollander P, Jensen MD & Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006 368 1660-1672. (Pubitemid 46048528)
69. Despres JP, Golay A & Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 2005 353 2121-2134. (Pubitemid 41653104)
70. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, RuzylloW, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM & Tuzcu EM. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Journal of the American Medical Association 2008 299 1547-1560.
71. 1 receptor antagonists for the treatment of metabolic disorders. Best Practice & Research. Clinical Endocrinology & Metabolism 2009 23 103-116.
72. Curioni C & Andre C. Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews, 2006. Issue 4 CD006162.
73. Christensen R, Kristensen PK, Bartels EM, Bliddal H & Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007 370 1706-1713. (Pubitemid 350100788)
74. Cleland SJ & Sattar N. Does rimonabant pull its weight for type 2 diabetes? Lancet 2006 368 1632-1634.
75. Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, Shen CP, Lao J, Xiao JC, Shearman LP, Stribling DS, Rosko K, Strack A, Marsh DJ, Feng Y, Kumar S, Samuel K, Yin W, Van der Ploeg LH, Goulet MT & Hagmann WK. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)- 1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}-propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. Journal of Medicinal Chemistry 2006 49 7584-7587. (Pubitemid 46033647)
76. Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE & Shearman LP. Antiobesityefficacy of a novel cannabinoid-1 receptor inverse agonist,N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. Journal of Pharmacology and Experimental Therapeutics 2007 321 1013-1022. (Pubitemid 46762708)
77. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohorquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN III, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depre M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM & Heymsfield SB. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metabolism 2008 7 68-78.
78. Viveros MP, de Fonseca FR, Bermudez-Silva FJ & McPartland JM. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocrine, Metabolic & Immune Disorders Drug Targets 2008 8 220-230.
79. Ohlsen RI & Pilowsky LS. The place of partial agonism in psychiatry: recent developments. Journal of Psychopharmacology 2005 19 408-413.
80. Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Merce R, Holenz J, Vrang N, Sorensen RV, Heal D, Buschmann H & Pauwels PJ. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. British Journal of Pharmacology 2006 148 973-983. (Pubitemid 44543615)
81. Pavon FJ, Bilbao A, Hernandez-Folgado L, Cippitelli A, Jagerovic N, Abellan G, Rodriguez-Franco MA, Serrano A, Macias M, Gomez R, Navarro M, Goya P & Rodriguez de Fonseca F. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3- hexyl-1H-1,2,4-triazole - LH 21. Neuropharmacology 2006 51 358-366.
82. Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, Feltrin D, Igreja SC, Ajodha S, Harvey-White J, Kunos G, Muller B, Pralong F, Aubert G, Arnaldi G, Giacchetti G, Boscaro M, GrossmanAB&KorbonitsM.AMP-activated proteinkinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB Journal 2008 22 1672-1683. (Pubitemid 351811445)
83. Okamoto Y, Morishita J, Tsuboi K, Tonai T & Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. Journal of Biological Chemistry 2004 279 5298-5305. (Pubitemid 38220550)
84. Tsou K, Nogueron MI, Muthian S, Sanudo-Pena MC, Hillard CJ, Deutsch DG & Walker JM. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neuroscience Letters 1998 254 137-140. (Pubitemid 28459400)